Scribd
Upload
87 views11 pages

Nonlinear Pharmacokinetics 1

This document discusses nonlinear pharmacokinetics where drug elimination does not follow first-order kinetics. It can occur due to saturation of drug metabolizing enzymes at higher doses. This leads to a longer drug half-life and non-proportional increases in drug exposure with higher doses. Michaelis-Menten kinetics is used to model saturable drug elimination, with Vmax being the maximum elimination rate and KM reflecting the enzyme system capacity. Drug concentrations above KM lead to zero-order elimination at a fixed rate of Vmax.

Uploaded by

Mubashar Shahid
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
87 views11 pages

Nonlinear Pharmacokinetics 1

This document discusses nonlinear pharmacokinetics where drug elimination does not follow first-order kinetics. It can occur due to saturation of drug metabolizing enzymes at higher doses. This leads to a longer drug half-life and non-proportional increases in drug exposure with higher doses. Michaelis-Menten kinetics is used to model saturable drug elimination, with Vmax being the maximum elimination rate and KM reflecting the enzyme system capacity. Drug concentrations above KM lead to zero-order elimination at a fixed rate of Vmax.

Uploaded by

Mubashar Shahid
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 11

NONLINEAR

PHARMACOKINETICS
INTRODUCTION
• Linear models assumed that the pharmacokinetic
parameters for a drug would not change when different
doses or multiple doses of a drug were given.
• But with some drugs, increased doses or chronic
medication can cause deviations from the linear
pharmacokinetic profile previously observed with
single low doses of the same drug.
• This nonlinear pharmacokinetic behavior is also
termed dose-dependent pharmacokinetics.
• Many of the processes of drug absorption, distribution,
biotransformation, and excretion involve enzymes or
carrier-mediated systems, one of these specialized
processes may become saturated
• drugs may demonstrate nonlinear pharmacokinetics
due to a pathologic alteration in drug absorption,
distribution, and elimination.
• For example, aminoglycosides may cause renal
nephrotoxicity, thereby altering renal drug excretion.
Drugs that demonstrate saturation kinetics show the
following characteristics.
1. Drug elimination does not follow first-order kinetics
2. The elimination half-life changes as dose is increased.
Usually, the elimination half-life increases with
increased dose due to saturation of an enzyme system
3. AUC is not proportional to the amount of bioavailable
drug
4. Saturation of capacity-limited processes may be
affected by other drugs that require the same enzyme
or carrier mediated system (i.e, competition effects).
5. The composition and/or ratio of the metabolites of a
drug may be affected by a change in the dose
Plasma level–time curves for a drug that
exhibits a saturable elimination process.
Curves A and B represent high and low
doses of durg, respectively, given in a
single IV bolus.
Curve C represents the normal first-order
elimination of a different drug.
SATURABLE ENZYMATIC ELIMINATION
PROCESSES
• The elimination of drug by a saturable enzymatic process
is described by Michaelis–Menten kinetics.
• If C p is the concentration of drug in the plasma, then
Elimination rate = dCp = VmaxCp
dt KM+Cp
• Vmax is the maximum elimination rate
• KM is the Michaelis constant that reflects the capacity of
the enzyme system. It is equal to the drug concentration
or amount of drug in the body at 0.5V max .
• The values for KM and Vmax are dependent on the
nature of the drug and the enzymatic process involved.
• When the drug concentration C p is large in relation to K M (C p >> K m),
saturation of the enzymes occurs and the value for K M is negligible.
• The rate of elimination proceeds at a fixed or constant rate equal to V max .
• Thus, elimination of drug becomes a zero-order process and Equation
becomes:

- dCp = VmaxCp = Vmax


dt Cp

A saturable process can also exhibit linear elimination when drug


concentrations are much less than enzyme concentrations. When the drug
concentration C p is small in relation to the K M, the rate of drug elimination
becomes a first-order process.
When given in therapeutic doses, most drugs produce plasma drug
concentrations well below K M for all carrier-mediated enzyme systems
affecting the pharmacokinetics of the drug. Therefore, most drugs at normal
therapeutic concentrations follow first-order rate processes.
DRUG ELIMINATION BY CAPACITY-LIMITED
PHARMACOKINETICS: ONE COMPARTMENT
MODEL, IV BOLUS INJECTION
• The rate of elimination of a drug that follows
capacity-limited pharmacokinetics is governed by the
Vmax and KM of the drug.
• If a single IV bolus injection of drug (D0) is given at
t = 0, the drug concentration (Cp) in the plasma at any
time t may be calculated by an integrated form of
previous Equation as
Co-Cp = Vmax – KM ln Co
t t Cp
Alternatively, the amount of drug in the body after an
IV bolus injection may be calculated by the following
relationship
Do-Dt = Vmax – KM ln Do
t t Dt
It may be used to simulate the decline of drug in the
body after various size doses are given, provided the
KM and Vmax of drug are known.
.
• In order to calculate the time for the dose of the drug to decline to
a certain amount of drug in the body, Equation 9.5 must be
rearranged and solved for time t:
• The one-compartment open model with capacity-
limited elimination pharmacokinetics adequately
describes the plasma drug concentration–time profiles
for some drugs.
• The mathematics needed to describe nonlinear
pharmacokinetic behavior of drugs that follow two-
compartment models and/or have both combined
capacity-limited and first-order kinetic profiles are
very complex and have little practical application for
dosage calculations and therapeutic drug monitoring

You might also like